A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the efficacy and safety of NPC-21 when administered
prophylactically to cytomegalovirus (CMV) seronegative patients receiving a first kidney
transplant from a CMV seropositive donor.